HAIFA, Israel, Feb. 18, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics, Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of placental or adipose (fat) stromal cells, Pluristem’s key technology platform. Patent claims also include methods of treatment using placental cells for numerous diseases including graft vs. host disease (GvHD), heart disease, stroke, burns, loss of tissue, loss of blood, anemia, and autoimmune disorders. Patents with similar claims have also been granted to Pluristem in Russia and in South Africa. This marks Pluristem’s third patent issued in Australia and its 28th patent issued worldwide.

Pluristem’s PLacental eXpanded (PLX) PAD cells have been approved for a Phase I study in Australia for the treatment of Pulmonary Arterial Hypertension (PAH). United Therapeutics will be conducting the trial under a licensing agreement with Pluristem.

“Australia represents a significant and attractive healthcare market for the largest biotech and pharmaceutical companies. Because this patent covers manufacturing methods for producing commercial quantities of cells, it is very valuable intellectual property for Pluristem and the patent can be a key asset for potential partnership and licensing opportunities for us in Australia,” stated Zami Aberman, Chairman and CEO of Pluristem.

Pluristem’s Australian patent announced on January 8, 2014 covers the use of adherent placental cells for the treatment of ischemia, which is a restriction of blood supply to tissues, and for treatments of conditions requiring connective tissue repair or regeneration.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

Pompano Beach, Feb. 10, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced it has signed an agreement with a global healthcare company that ranks in the top 200 of the Fortune Global 500 list of largest corporations in the world in 2013. Per the terms of the agreement, DS Healthcare is providing the formulation, ingredients and its technology to the global healthcare company for use in a topical product. The product is to be launched and distributed by the global healthcare company under their own brand following successful development. Under the terms of the agreement, DS Healthcare will act as the exclusive ingredient supplier for a period of 5 years, which will automatically renew under certain conditions.

“This agreement with a leader in the global healthcare market is a clear indication of the strength of our innovation. DS Healthcare has built a reputation of excellence for our products that has led to this agreement. This is an exciting project that we believe will reach new milestones for us,” stated DS Healthcare President and CEO Daniel Khesin.

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group’s flagship brand, visit www.dslaboratories.com

Forward-looking statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies, and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.

WILMINGTON, Mass., Feb. 13, 2014 /PRNewswire/ — Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has won an order for its QS-H150 handheld explosives trace detectors (ETD), associated consumables, and services. The total value of the order including consumables and service is expected to be approximately $1,500,000, with the first $1,000,000 to be delivered to the customer during Implant Sciences’ fiscal year 2014 for deployment in Latin America.

Hector Giraldo, Managing Director, Americas for Implant Sciences commented, “We have been supplying trace detection equipment to Latin America since 2008. Our ETDs are widely used across the region and our reputation for performance was a key factor in winning this contract. The customer also clearly favored our systems’ non-radioactive source and non-contact particle sampling technology.”

“Latin America is a market which holds great growth potential for us. Hector has done a great job of expanding our presence in the region,” added Implant Sciences’ Vice President of Sales and Marketing, Dr. Darryl Jones. “Our superior technology, regulatory approvals, and excellent sales and service combine to expand our global footprint.”

About the QS-H150 Handheld Explosives Trace Detector

The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.